Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Nilotinib as the First-line Treatment for Patients With Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia: a Prospective Study

NCT03942094 is registered in ClinicalTrials.gov with Shenzhen Second People's Hospital as lead sponsor.

NCT NCT03942094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03942094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Nilotinib as the First-line Treatment for Patients With Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia: a Prospective Study
Lead sponsor
Shenzhen Second People's Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
June 1, 2019
Completion date
December 1, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, chronic phase, nilotinib